Transgene (TNG) Corporate Presentation summary

Strategic focus and pipeline highlights

• Developing viral vector-based immunotherapies, with lead program TG4050 targeting early solid tumors and aiming for significant value creation between 2025 and 2028.

• myvac® platform leverages AI-driven neoantigen selection for individualized cancer vaccines, with TG4050 as the leading candidate.

• Additional assets include TG4001 for HPV+ cancers, BT-001 and TG6050 oncolytic viruses for solid tumors, and ongoing research to expand the portfolio.

• Business funded through April 2026, supporting key clinical milestones and new trial initiations.

• New leadership team with extensive industry experience guiding the next phase of growth.

TG4050 clinical progress and data

• Phase I trial in head and neck cancer showed 100% disease-free survival at 24 months for TG4050-treated patients, with no relapses versus 81% DFS in the control arm.

• Persistent, neoantigen-specific CD8+ T cell responses observed over a year post-treatment, indicating durable immunogenicity.

• Ongoing Phase II trial with last patient randomization expected in Q4 2025; additional Phase I trial in a new indication planned for Q4 2025.

• TG4050 demonstrated a strong safety profile and potential to extend remission in high-risk populations.

• AI-powered neoantigen identification and scalable manufacturing enable individualized vaccine production.

Other pipeline assets and clinical updates

• BT-001, an oncolytic virus armed with anti-CTLA4 and GM-CSF, showed promising antitumor activity in combination with anti-PD1; further data expected H2 2025.

• TG6050, an oncolytic virus with IL-12 and anti-CTLA4, is in Phase I for metastatic NSCLC; initial data expected Q2 2025.

• TG4001 Phase II trial in HPV16+ cancers did not meet the primary endpoint but showed positive trends in cervical cancer subgroups; partnership opportunities are being explored.

• Oncolytic virus platforms support multiple administration routes and target a broad range of solid tumors.